LBRX compared with AVTX: revenue, margins and what each company keeps, and the suppliers and customers both name

LBRXLB Pharmaceuticals Inc

Mkt capRevenueRevenue

AVTXAvalo Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

LBRXLB Pharmaceuticals Inc

AVTXAvalo Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

LBRX

Reportimpliedrealized× implied

Q2 FY26—▼−1.13%—

May 13 '26—▲+3.79%—

Q1 FY26—▼−2.81%—

Q3 FY25—▼−4.26%—

AVTX2 of 4 reports

0 of 2at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±16.8%▼−6.22%×0.37

Q2 FY26±19.6%▼−0.74%×0.04

= impliedLBRX realized, solidAVTX realized, hatchedOne scale, both sides: full bar = 20%× = |realized| ÷ impliedspan: LBRX 278d · AVTX 91dSource: market data

LBRXLB Pharmaceuticals Inc

38.72· pre 38.66· delayed

Mkt cap$1.3BRevenue—

AVTXAvalo Therapeutics, Inc.

6.64· pre 6.89· delayed

Pre-marketNov 6 '26delayed

Mkt cap$383.4MRevenue$59,000Q4 FY25

Compare

Pre-marketNov 6 '26delayed

LBRXLB Pharmaceuticals Inc

AVTXAvalo Therapeutics, Inc.

38.72pre 38.66delayed

Price

6.64pre 6.89delayed

$1.3B

Mkt cap

$383.4M

—

Revenue

$59,000Q4 FY25

LBRX38.72vsAVTX6.64Pre-marketNov 6 '26delayed